Unauited Financial Results along with Limited Review Report for the quarter ended 31.12.2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Arunjyoti Bio Ventures reported Q3 FY26 revenue of ₹646.82 lakhs, a sequential recovery from ₹533.65 lakhs in Q2 FY26 and slightly above ₹615.38 lakhs in Q3 FY25. For the nine months ended December 2025, revenue stood at ₹2,051.71 lakhs, down about 9% from ₹2,260.30 lakhs in the same period last year. The company swung to a profit after tax of ₹4.87 lakhs in Q3 FY26, compared to a loss of ₹88.76 lakhs in Q3 FY25, while 9-month PAT rose to ₹86.48 lakhs from ₹74.90 lakhs. Total expenses fell sharply on a nine-month basis, helping margins recover. Auditor PKF Sridhar & Santhanam LLP issued an unmodified review report with an emphasis of matter on a prior-period deferred tax correction under Ind AS 8, and noted that prior period figures were reviewed/audited by a predecessor auditor.
The turnaround to a small quarterly profit and the 15% rise in nine-month PAT are mildly positive, but nine-month revenue is still shrinking and earnings remain thin relative to the equity base. The auditor change and the restatement of prior deferred tax figures add a layer of caution for investors.